

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025**SECTION 1. IDENTIFICATION**

Product name : TECENTRIQ HYBREZA Vials 1875 mg/15 ml

Product code : RO554-1267/F06-02

Common name(s),
synonym(s) of the substance : Atezolizumab SC (Subcutaneous) 12,5% aqueous solution
with excipients and Hyaluronidase

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Atezolizumab	1380723-44-3	12.5
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	8.22
L-Histidine	71-00-1	0.31
L-Methionine	63-68-3	0.15
Acetic acid	64-19-7	0.08
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.06

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

Hyaluronidase	757971-58-7	0.0027
Water	7732-18-5	78

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.
- If inhaled : If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : Wash off with soap and water.
- In case of eye contact : Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
- Most important symptoms and effects, both acute and delayed : None known.
- Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing
- Notes to physician : Treat symptomatically.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : Carbon monoxide
Nitrogen oxides (NO_x)
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

Special protective equipment : Wear self-contained breathing apparatus for firefighting if
for fire-fighters necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, : Refer to protective measures listed in sections 7 and 8.
protective equipment and
emergency procedures

Environmental precautions : If the product contaminates rivers and lakes or drains inform
respective authorities.

Methods and materials for : Wipe up with absorbent material (e.g. cloth, fleece).
containment and cleaning up Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against : Normal measures for preventive fire protection.
fire and explosion

Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the
application area.

Conditions for safe storage : Electrical installations / working materials must comply with
the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protect from heat and light

Further information on : No decomposition if stored and applied as directed.
storage stability

Packaging material : Suitable material: Stainless steel, glass, Vials

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Atezolizumab	1380723-44-3	IOEL	0.220 mg/m ³	Roche Industrial Hygiene Committee (RIHC)
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m ³	ACGIH

TECENTRIQ HYBREZA Vials 1875 mg/15 ml

 Version
 1.0

 Revision Date:
 06/15/2025

 Date of last issue: -
 Date of first issue: 06/15/2025

		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0
Hyaluronidase	757971-58-7	IOEL	0.00006 mg/m3	Roche Industrial Hygiene Committee (RIHC)

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

In case of contact through splashing:

Material : Nitrile rubber
 Break through time : > 30 min
 Glove thickness : > 0.11 mm

In case of full contact:

Material : butyl-rubber
 Break through time : > 480 min
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : General industrial hygiene practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

Appearance	:	Aqueous solution, Clear liquid, Sterile liquid
Color	:	colorless
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	5.8
Melting point/ range	:	No data available
Boiling point/boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Self-ignition	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics
Particle Size Distribution : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created

Stable under normal conditions.Possibility of hazardous reactions : Stable under recommended storage conditions.
No hazards to be specially mentioned.Conditions to avoid : No data available

No data availableIncompatible materials : No data available

Not applicableHazardous decomposition products : No data available

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified due to lack of data.

Components:**Atezolizumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025**Hyaluronidase:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Skin corrosion/irritation

Not classified due to lack of data.

Components:**Hyaluronidase:**

Remarks : This information is not available.

Serious eye damage/eye irritation

Not classified due to lack of data.

Components:**Hyaluronidase:**

Remarks : This information is not available.

Respiratory or skin sensitization**Skin sensitization**

Not classified due to lack of data.

Respiratory sensitization

Not classified due to lack of data.

Components:**Hyaluronidase:**

Remarks : May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

Germ cell mutagenicity

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative**Carcinogenicity**

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified due to lack of data.

Components:**Atezolizumab:**

Effects on fetal development : Species: Humans
Result: Critical exposure in human after parenteral administration only

Species: Humans
Result: Parenteral administration to pregnant women can cause fetal harm

STOT-single exposure

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025**Repeated dose toxicity****Components:****Hyaluronidase:**

Species : cynomolgus monkey
NOAEL : 2 mg/kg/w
Application Route : s.c.
Exposure time : 39 weeks

Aspiration toxicity

Not classified due to lack of data.

Components:**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

Hyaluronidase:

No data available

Further information**Product:**

Remarks : No data available

Components:**Atezolizumab:**

Remarks : after parenteral application, rare cases of hypersensitivity, including anaphylactic shock, can occur

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:

Remarks : Health injuries are not known or expected under normal use.

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to
the environment : No data available**Hyaluronidase:****Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to
the environment : No data available**Persistence and degradability****Components:****Atezolizumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

Hyaluronidase:

Biodegradability : Result: Globular proteins are generally well biodegradable

Bioaccumulative potential**Components:****Atezolizumab:**Partition coefficient: n-
octanol/water : Remarks: No data available**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**Partition coefficient: n-
octanol/water : log Pow: -3.7 (68 °F / 20 °C)**Hyaluronidase:**Partition coefficient: n-
octanol/water : Remarks: No data available**Mobility in soil**

No data available

Other adverse effects**Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I
Substances
Remarks: This product neither contains, nor was
manufactured with a Class I or Class II ODS as defined by the
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +
B).

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025Additional ecological
information : No data available**Components:****Atezolizumab:**Additional ecological
information : Monoclonal antibodies are proteins with highly specific affinity
to a certain antigen; therefore, no appreciable ecotoxic
potential is to be expected**Hyaluronidase:**Additional ecological
information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**Waste from residues : Can be disposed as waste water, when in compliance with
local regulations.Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for userRemarks : Not dangerous goods in the meaning of ADR/RID, ADN,
IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION**CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

TECENTRIQ HYBREZA Vials 1875 mg/15 ml

 Version
 1.0

 Revision Date:
 06/15/2025

 Date of last issue: -
 Date of first issue: 06/15/2025

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

SARA 311/312 Hazards : No SARA Hazards

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

The following Hazardous Substances are listed under the U.S. Clean Water Act, Section 311, Table 116.4A:

Acetic acid 64-19-7 >= 0 - < 0.1 %

The following Hazardous Chemicals are listed under the U.S. Clean Water Act, Section 311, Table 117.3:

Acetic acid 64-19-7 >= 0 - < 0.1 %

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations
Massachusetts Right To Know

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know

Water	7732-18-5
Atezolizumab	1380723-44-3
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1
Acetic acid	64-19-7

Maine Chemicals of High Concern
Vermont Chemicals of High Concern
Washington Chemicals of High Concern
California Permissible Exposure Limits for Chemical Contaminants

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

The ingredients of this product are reported in the following inventories:

AICC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Atezolizumab

TECENTRIQ HYBREZA Vials 1875 mg/15 ml

 Version
 1.0

 Revision Date:
 06/15/2025

 Date of last issue: -
 Date of first issue: 06/15/2025


Hyaluronidase

NZIoC	: On the inventory, or in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION
Further information
NFPA 704:

HMIS® IV:

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

TECENTRIQ HYBREZA Vials 1875 mg/15 mlVersion
1.0Revision Date:
06/15/2025Date of last issue: -
Date of first issue: 06/15/2025

NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/15/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

SAFETY DATA SHEET

TECENTRIQ HYBREZA Vials 1875 mg/15 ml

Version
1.0

Revision Date:
06/15/2025

Date of last issue: -
Date of first issue: 06/15/2025

US / EN / 2404